Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jeong Mi Yang"'
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-16 (2018)
Abstract Background Antitumor immune response of programmed cell death ligand (PD-L1) has shown clinical value not only in Hodgkin lymphoma and EBV-associated lymphomas but also in EBV-negative diffuse large B cell lymphoma (DLBCL) of non-germinal ce
Externí odkaz:
https://doaj.org/article/27930e672a1c465e822009a95817e49f
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-14 (2018)
Abstract Background Diffuse large B cell lymphoma (DLBCL) contains heterogeneous subtypes with various molecular dysregulation at the gene, protein and microRNA levels. Compared with the GCB subtype, the non-germinal center B-like (non-GCB)/activated
Externí odkaz:
https://doaj.org/article/783652532ad34800a7083e6aadd89619
Publikováno v:
Anticancer research. 41(11)
BACKGROUND/AIM Bruton's tyrosine kinase (BTK)-mediated B-cell-receptor signaling drives lymphomagenesis of diffuse large B-cell lymphoma (DLBCL). We investigated the clinicopathological significance of BTK positivity in DLBCL according to known molec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d13debbda6dafca3199ab8efbea8498
https://pubmed.ncbi.nlm.nih.gov/34732441
https://pubmed.ncbi.nlm.nih.gov/34732441
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-14 (2018)
Journal of Translational Medicine
Journal of Translational Medicine
Background Diffuse large B cell lymphoma (DLBCL) contains heterogeneous subtypes with various molecular dysregulation at the gene, protein and microRNA levels. Compared with the GCB subtype, the non-germinal center B-like (non-GCB)/activated B cell-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f0f1d670260483aa6d3a410a20e4973
http://link.springer.com/article/10.1186/s12967-018-1537-0
http://link.springer.com/article/10.1186/s12967-018-1537-0
Autor:
Choon Taek Lee, Jin Ho Paik, Yan Jin, Jin-Haeng Chung, Kwhanmien Kim, Jeong Mi Yang, Hyojin Kim, Sanghoon Jheon
Publikováno v:
Oncotarget
// Hyojin Kim 1 , Jeong Mi Yang 1 , Yan Jin 1 , Sanghoon Jheon 2 , Kwhanmien Kim 2 , Choon Taek Lee 3 , Jin-Haeng Chung 1 , Jin Ho Paik 1 1 Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea 2 Department of Thoracic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39438345f18143eb68c2e3ae46a0a1dc
https://doi.org/10.18632/oncotarget.14298
https://doi.org/10.18632/oncotarget.14298
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-16 (2018)
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-16 (2018)
Background Antitumor immune response of programmed cell death ligand (PD-L1) has shown clinical value not only in Hodgkin lymphoma and EBV-associated lymphomas but also in EBV-negative diffuse large B cell lymphoma (DLBCL) of non-germinal center B ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f0ebb5e4af57fce3d487aece0e203ee
https://doi.org/10.1186/s12967-018-1689-y
https://doi.org/10.1186/s12967-018-1689-y
Publikováno v:
Anticancer research. 38(9)
BACKGROUND Altered microRNA expression is associated with cancer progression. This study investigated the prognostic significance of microRNA-155-5p (miR-155-5p), a well-known oncomiR, in oral squamous cell carcinoma (OSCC). MATERIALS AND METHODS miR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8fe17c05326876014f6f86150bce80
https://pubmed.ncbi.nlm.nih.gov/30194167
https://pubmed.ncbi.nlm.nih.gov/30194167
Publikováno v:
Genes, chromosomescancer. 57(5)
The A20/Tumor necrosis factor-alpha-induced protein 3 (A20/TNFAIP3) is a negative regulator of NF-κB signaling. We analyzed the clinicopathologic implications of A20 deletions in extranodal NK/T-cell lymphoma (NKTL). Fluorescence in situ hybridizati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::742d1d9b99aee332fde33bbf8386a67a
https://pubmed.ncbi.nlm.nih.gov/29380463
https://pubmed.ncbi.nlm.nih.gov/29380463
Autor:
Soon Hyun Ahn, Jin Ho Paik, Woo Jin Jeong, Jeong Mi Yang, Hyojin Kim, Hyein Ahn, Jin Haeng Chung
Publikováno v:
Oncotarget
// Hyein Ahn 1 , Jeong Mi Yang 1 , Hyojin Kim 1 , Jin-Haeng Chung 1 , Soon-Hyun Ahn 2 , Woo-Jin Jeong 2 and Jin Ho Paik 1 1 Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bf72f146d1d163a651198de76642838
https://pubmed.ncbi.nlm.nih.gov/29029502
https://pubmed.ncbi.nlm.nih.gov/29029502